tiprankstipranks
PAVmed Reports Record Revenue and Strategic Restructuring
Company Announcements

PAVmed Reports Record Revenue and Strategic Restructuring

Pick the best stocks and maximize your portfolio:

The latest announcement is out from PAVmed ( (PAVM) ).

PAVmed Inc., a diversified medical technology company, has made significant strides in solidifying its business with record quarterly revenue from Lucid’s EsoGuard tests and a strategic debt restructuring to maintain its Nasdaq listing. The company reported notable achievements, such as completing the clinical package for Medicare coverage submission and securing an NIH grant for Veris Health. Despite financial challenges, including a decrease in cash reserves, PAVmed continues to focus on growth and strategic partnerships, positioning itself for a promising future in the life sciences sector.

Learn more about PAVM stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyLucid announces publication on EsoGuard in peer-reviewed journal Medicina
TheFlyLucid Diagnostics completes convertible debt refinancing
TheFlyLucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App